TABLE 2.
Pulmonary Exacerbation Events and Health Care Resource Utilization 180 Days Before and After ELX/TEZ/IVA New Initiation
| 180-day preperiod | 180-day postperiod | Difference (% change) | P value | |||
|---|---|---|---|---|---|---|
| Pulmonary exacerbation events | ||||||
| Total number of pulmonary exacerbation events | 726 | — | 406 | — | -44.1 | < 0.001 |
| Mean (SD) | 1.47 | (1.29) | 0.82 | (1.0) | ||
| Number of pulmonary exacerbation events (categorical) per member, n (%) | ||||||
| 0 | 130 | (26.3) | 236 | (47.8) | ||
| ≥1 | 364 | (73.7) | 258 | (52.2) | ||
| All-cause health care resource utilization | ||||||
| Inpatient hospitalizations | ||||||
| Total number of inpatient hospitalizations | 202 | — | 77 | — | -61.9 | < 0.001 |
| Mean (SD) | 0.41 | (0.89) | 0.16 | (0.59) | ||
| Number of inpatient hospitalizations (categorical) per member, n (%) | ||||||
| 0 | 370 | (74.9) | 446 | (90.3) | ||
| ≥1 | 124 | (25.1) | 48 | (9.7) | ||
| Emergency department visits | ||||||
| Total number of emergency department visits | 152 | — | 87 | — | -42.8 | < 0.001 |
| Mean (SD) | 0.30 | (1.08) | 0.18 | (0.66) | ||
| Number of emergency department visits (categorical) per member, n (%) | ||||||
| 0 | 410 | (83.0) | 438 | (88.7) | ||
| ≥1 | 84 | (17.0) | 56 | (11.3) | ||
All members naive to cystic fibrosis transmembrane conductance regulator therapy and newly initiating ELX/TEZ/IVA.
ELX/TEZ/IVA = elexacaftor/tezacaftor/ivacaftor.